靈(ling)康(kang)藥(yao)(yao)(yao)(yao)業公告，5月(yue)7日，公司與海(hai)(hai)(hai)南(nan)(nan)省(sheng)腫(zhong)(zhong)瘤(liu)(liu)(liu)醫(yi)院在(zai)海(hai)(hai)(hai)南(nan)(nan)簽(qian)署了《戰略(lve)合(he)作協(xie)議》。雙方擬共(gong)同(tong)打(da)造(zao)醫(yi)藥(yao)(yao)(yao)(yao)先行先試產(chan)業化(hua)平(ping)臺。充分利用博鰲(ao)樂城國家臨(lin)(lin)床醫(yi)學(xue)(xue)創(chuang)新(xin)(xin)中(zhong)(zhong)心和(he)先進技術臨(lin)(lin)床醫(yi)學(xue)(xue)研(yan)究(jiu)中(zhong)(zhong)心，聚焦于藥(yao)(yao)(yao)(yao)物臨(lin)(lin)床試驗，轉化(hua)醫(yi)學(xue)(xue)及新(xin)(xin)技術應(ying)用、精準醫(yi)療(liao)等(deng)(deng)。雙方成立醫(yi)藥(yao)(yao)(yao)(yao)聯合(he)研(yan)發小組，重點關注領(ling)域(yu)包括抗(kang)腫(zhong)(zhong)瘤(liu)(liu)(liu)、心血(xue)管、消化(hua)系統等(deng)(deng)大(da)病種領(ling)域(yu)創(chuang)新(xin)(xin)藥(yao)(yao)(yao)(yao)及仿制(zhi)藥(yao)(yao)(yao)(yao)。海(hai)(hai)(hai)南(nan)(nan)省(sheng)腫(zhong)(zhong)瘤(liu)(liu)(liu)醫(yi)院將優(you)(you)(you)先采購(gou)靈(ling)康(kang)藥(yao)(yao)(yao)(yao)業的(de)藥(yao)(yao)(yao)(yao)品(pin)(pin)。海(hai)(hai)(hai)南(nan)(nan)省(sheng)腫(zhong)(zhong)瘤(liu)(liu)(liu)醫(yi)院研(yan)發出(chu)的(de)新(xin)(xin)藥(yao)(yao)(yao)(yao)品(pin)(pin)，優(you)(you)(you)先通過靈(ling)康(kang)藥(yao)(yao)(yao)(yao)業生(sheng)產(chan)和(he)銷售。靈(ling)康(kang)藥(yao)(yao)(yao)(yao)業的(de)產(chan)品(pin)(pin)，海(hai)(hai)(hai)南(nan)(nan)省(sheng)腫(zhong)(zhong)瘤(liu)(liu)(liu)醫(yi)院在(zai)同(tong)等(deng)(deng)條件下享有優(you)(you)(you)先采購(gou)權。